Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program

Nino Keshelava, Peter J. Houghton, Christopher L. Morton, Richard B. Lock, Hernan Carol, Stephen T. Keir, John M. Maris, C. Patrick Reynolds, Richard Gorlick, E. Anders Kolb, Jianrong Wu, Malcolm A. Smith

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Vorinostat, a histone deacetylase inhibitor, was evaluated against the in vitro and in vivo childhood solid tumor and leukemia models in the Pediatric Preclinical Testing Program (PPTP). In vitro testing was performed by the DIMSCAN cytotoxicity assay. In vivo, vorinostat was administered intraperitoneally to mice bearing xenografts. Vorinostat demonstrated 2-log cell growth inhibitory activity in vitro, but generally at concentrations not sustainable in the clinic. No objective responses were observed for any of the solid tumor or acute lymphoblastic leukemia xenografts. Preclinical studies with appropriate drug combinations may provide direction for further clinical evaluations of vorinostat against selected pediatric cancers.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalPediatric Blood and Cancer
Issue number3
StatePublished - Sep 2009
Externally publishedYes


  • Developmental therapeutics
  • Preclinical testing
  • Vorinostat

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program'. Together they form a unique fingerprint.

Cite this